Teva completes Cephalon acquisition

JERUSALEM — Teva Pharmaceutical Industries has completed its acquisition of another drug maker, following clearance from the Federal Trade Commission.

Teva said its acquisition of Frazier, Pa.-based Cephalon, valued at $6.8 billion, will help the company build out its branded and specialty pharmaceuticals business. The combined company is expected to generate about $20 billion in revenues (on a pro-forma basis) for the 12 months ended in June.

In relation to the deal, Teva sold three generic drugs to Par Pharmaceutical Cos.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.